Provexis (PXSL) Stock Overview

Develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. More details

PXSL fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 13.2% per year over past 5 years

Shares are highly illiquid

Latest financial reports are more than 6 months old

Does not have a meaningful market cap (£28M)

+ 1 more risk

PXSL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW485,349 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

485,349 investors already sharing narratives

View all narratives

Provexis plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Provexis
Historical stock prices
Current Share Price	UK£0.008
52 Week High	UK£0.014
52 Week Low	UK£0.008
Beta	0.67
1 Month Change	0%
3 Month Change	n/a
1 Year Change	8.78%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	8.78%

Recent updates

Shareholder Returns

	PXSL	GB Personal Products	GB Market
7D	0%	-2.0%	1.2%
1Y	8.8%	-8.4%	17.0%

Return vs Industry: PXSL exceeded the UK Personal Products industry which returned -8.4% over the past year.

Return vs Market: PXSL underperformed the UK Market which returned 17% over the past year.

Price Volatility

Is PXSL's price volatile compared to industry and market?
PXSL volatility
PXSL Average Weekly Movement	n/a
Personal Products Industry Average Movement	5.5%
Market Average Movement	5.1%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: PXSL's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine PXSL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	2	Ian Ford	www.provexis.com

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product.

Provexis plc Fundamentals Summary

How do Provexis's earnings and revenue compare to its market cap?
PXSL fundamental statistics
Market cap	UK£28.03m
Earnings (TTM)	-UK£603.80k
Revenue (TTM)	UK£871.27k

32.2x

P/S Ratio

-46.4x

P/E Ratio

Is PXSL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PXSL income statement (TTM)
Revenue	UK£871.27k
Cost of Revenue	UK£442.30k
Gross Profit	UK£428.97k
Other Expenses	UK£1.03m
Earnings	-UK£603.80k

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.00026
Gross Margin	49.24%
Net Profit Margin	-69.30%
Debt/Equity Ratio	0%

How did PXSL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/26 16:37
End of Day Share Price	2026/06/12 00:00
Earnings	2025/09/30
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Provexis plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Provexis plcBATS-CHIXE:PXSL Stock Report